2022
Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group
Tan W, Steinberg G, Witjes J, Li R, Shariat S, Roupret M, Babjuk M, Bivalacqua T, Psutka S, Williams S, Cookson M, Palou J, Kamat A. Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. European Urology Oncology 2022, 5: 505-516. PMID: 35718695, DOI: 10.1016/j.euo.2022.05.005.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder cancer groupManagement of patientsIntermediate-riskIntravesical treatmentCancer groupRisk factorsClinical trialsIntravesical chemotherapyMultifocal tumorsEarly recurrenceTumor sizeBladder cancerFrequent recurrenceHeterogeneous diseaseGrading systemCarcinoma in situStage of tumorPostoperative intravesical chemotherapyRandomized clinical trialsMaintenance BCGComparison of outcomesRecurrent diseaseClinical practice guidance
2016
Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia
Tan W, Rodney S, Lamb B, Feneley M, Kelly J. Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia. Cancer Treatment Reviews 2016, 47: 22-31. PMID: 27231966, DOI: 10.1016/j.ctrv.2016.05.002.Peer-Reviewed Original ResearchConceptsNon-muscle invasive bladder cancerBladder cancerAnalysis of guidelinesBladder cancer casesUnited StatesCancer casesInvasive bladder cancerIntravesical treatmentTransurethral resectionExpensive cancerTreatment modalitiesSurveillance protocolsContemporary guidelinesUnited KingdomGuidelinesIntensive treatmentBladderCancerInternational ConsultationTreatmentConsultationUnits